MaxCyte Announces Pricing of Upsized Offering and Approval to List on the Nasdaq Global Select Market

Published on : Published by : BioBuzz Media

MaxCyte, Inc., (LSE: MXCT, MXCN), a leading provider of cell-engineering platform technologies, today announced the pricing of its upsized offering of 13,500,000 shares of common stock at an initial offering price of US$13.00 per share (the “Offering”).

Rockville’s Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHD

Published on : Published by : BioBuzz Media

Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHD ROCKVILLE, Md., April 02, 2021 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products [….]